Current and emerging treatment options for patients with MF who are ineligible for ruxolitinib [Video]

Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, discusses the emerging and currently available treatment options for patients with myelofibrosis (MF) who are ineligible for ruxolitinib. Patients may be ineligible due to being at an early stage of the disease, in which case Prof. Harrison recommends using a pragmatic approach and multiple prognostic scores to ensure those who would benefit from ruxolitinib receive the drug. Ineligibility may also occur due to the presence of severe thrombocytopenia. For these patients, momelotinib was recently approved, pacritinib is being investigated in the Phase III PACIFICA trial (NCT03165734), and other non-JAK inhibitor treatment approaches are also being considered. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.